Moreover, the present study indicates that CXCR1/2 antagonist and Src family inhibitors or ß-catenin inhibitors may be promising pharmacological approaches in the treatment of advanced prostate carcinoma. The gene discussed is SRC; the disease is prostate carcinoma.